[1]肖汇颖,胡冬菊,贾海波,等.石龙解毒方治疗弥漫大B细胞淋巴瘤临床研究[J].陕西中医,2021,(4):478-481.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.019]
　XIAO Huiying,HU Dongju,JIA Haibo,et al.Effect of Shilong Jiedu recipe on serum beta 2-MG and LDH in patients with diffuse large B-cell lymphoma[J].,2021,(4):478-481.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.019]
点击复制

石龙解毒方治疗弥漫大B细胞淋巴瘤临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年4期
页码:
478-481
栏目:
临床研究
出版日期:
2021-04-05

文章信息/Info

Title:
Effect of Shilong Jiedu recipe on serum beta 2-MG and LDH in patients with diffuse large B-cell lymphoma
作者:
肖汇颖1; 胡冬菊1; 贾海波2; 王永敏1; 籍祥瑞1; 杨 凯1
(1.河北省中医院,河北 石家庄050011; 2.河北省人民医院中医科,河北 石家庄050011)
Author(s):
XIAO Huiying; HU Dongju; JIA Haibo; WANG Yongmin; JI Xiangrui; YANG Kai
(Hebei Provincial Hospital of Traditional Chinese Medicine,Shijiazhuang 050011,China)
关键词:
石龙解毒方;  弥漫大B细胞淋巴瘤;  血清β2-微球蛋白;  乳酸脱氢酶;  免疫功能;  化疗
Keywords:
Shilong Jiedu recipe;  Diffuse large B-cell lymphoma;  Serum beta 2-MG;  Lactate dehydrogenase;  Immune function;  Chemotherapy
分类号:
R 733.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.04.019
文献标志码:
A
摘要:
目的:观察石龙解毒方对弥漫大B细胞淋巴瘤患者血清β2-微球蛋白(β2-MG)与乳酸脱氢酶(LDH)的影响。方法:将弥漫大B细胞淋巴瘤80例患者按照随机对照法分为观察组和对照组,每组40例。对照组采用CHOP方案治疗,观察组在采用CHOP方案治疗的同时,口服石龙解毒汤辅助治疗。3周为1个疗程,连用6个疗程。观察两组治疗疗效,比较治疗前后中医证候积分、中医治疗疗效,治疗前后免疫细胞因子水平,β2-MG与LDH水平,两组不良反应发生情况。结果:观察组总有效率和对照组相比,差异无统计学意义(P>0.05); 观察组治疗后中医证候积分低于对照组(P<0.05); 观察组治疗后中医证候疗效高于对照组(P<0.05); 观察组治疗后血清β2-MG与LDH水平均低于对照组(P<0.05); 观察组治疗后CD3+、CD4+、CD19+ 细胞比例均明显高于对照组,CD8+ 细胞比例和对照组比较差异无统计学意义(P>0.05); 观察组不良反应总发生率低于对照组(P<0.05)。结论:石龙解毒方治疗弥漫大B细胞淋巴瘤疗效确切,能降低血清β2-MG与LDH水平,提高化疗患者的免疫力,减毒增效。
Abstract:
Objective:To observe the effect of Shilong Jiedu recipe on serum beta 2-MG and Lactate dehydroglobulin(LDH)in patients with diffuse large B-cell lymphoma.Methods:A total of 80 patients with diffuse large B-cell lymphoma were selected as the study subjects.According to the randomized control method,the patients were divided into observation group and control group,with 40 patients in each group.The patients in the control group were treated with CHOP regimen,while the patients in the observation group were treated with CHOP regimen,and the patients in the observation group were treated with Shilong Jiedu recipe.Three weeks course of treatment,six courses of treatment.Compared the curative effect of the two groups,the scores of TCM symptoms before and after treatment,the curative effect of TCM treatment,the levels of immune cytokines,beta 2-MG and LDH before and after treatment,and compare the occurrence of adverse reactions between the two groups.Results:There was no significant difference between the observation group and the control group(P>0.05).Observation group after treatment of TCM symptom score lower than the control group(P<0.05).Observation group after treatment of TCM symptoms curative effect was higher than the control group(P<0.05).Observation group after treatment serum beta 2 - MG and LDH level was lower than the control group(P<0.05).After treatment,the proportion of CD3+,CD4+ and CD19+ cells in the observation group was significantly higher than that in the control group,while the proportion of CD8+ cells in the observation group was not significantly different from that in the control group(P>0.05).Incidence of adverse reactions to the total observation group was lower than the control group(P<0.05).Conclusion:Shilong Jiedu recipe for diffuse large B cell lymphoma has a definite effect,can reduce the serum β2-MG and LDH levels,improve the immunity of chemotherapy patients,reduce toxicity and increase efficacy.

参考文献/References:

[1] 代兴斌,张文曦,孙雪梅,等.消癌平注射液辅助化疗治疗非霍奇金淋巴瘤的临床分析[J].广州中医药大学学报,2019,36(10):1497-1502.
[2] 封乃元,殷东风,高 宏,等.恶性淋巴瘤形神变化特点及中药用药规律[J].内蒙古中医药,2019,38(6):162-165.
[3] 孔 飞,张芳文,李 玲,等.弥漫大B细胞淋巴瘤分子遗传学研究进展[J].中华实用诊断与治疗杂志,2019,33(2):194-196.
[4] 李 慧,李 达.李达和血法病证融合辨治淋巴瘤的思路与经验[J].中华中医药杂志,2019,34(6):2522-2525.
[5] 聂金霞,陈 难,邓克红.当归补血汤对宫颈癌荷瘤小鼠抑瘤效果及对免疫调节作用的研究[J].陕西中医,2019,40(3):279-282.
[6] 籍祥瑞,肖汇颖,杨 凯,等.石龙解毒方对老年非霍奇金淋巴瘤患者中医证候及生活质量的影响[J].河北中医,2019,41(4):523-527.
[7] 梁碧琦,谭晓虹,孙 洁,等.利妥昔单抗与依鲁替尼对弥漫性大B细胞淋巴瘤细胞增殖和凋亡协同作用研究[J].中华肿瘤防治杂志,2017,24(8):535-539,545.
[8] 王 丹,周 英.祛湿化痰法对弥漫大B细胞淋巴瘤疗效及免疫水平的影响[J].湖北中医杂志,2019,41(6):13-15.
[9] 王志芳,刘 岩,肖 丽,等.ICE方案联合利妥昔单抗对难治性弥漫大B细胞淋巴瘤FOXP1与Livin表达影响研究[J].陕西医学杂志,2018,47(1):50-52,68.
[10] 阙喜妹,郗彦凤,王 彤.MiR-27a高表达对弥漫性大B细胞淋巴瘤患者预后的影响[J].中华疾病控制杂志,2018,22(10):1004-1007.
[11] 王鹏飞.复方君子汤配合CHOPE方案治疗复发难治性非霍奇金淋巴瘤临床研究[J].新中医,2019,51(8):190-193.
[12] 张 曼,赵旭林,徐全晓,等.DC-CIK调节弥漫大B细胞淋巴瘤患者细胞免疫功能的临床研究[J].中华全科医学,2019,17(8):1302-1304,1391.
[13] 王健红,梁 蓉.CD5和B细胞淋巴瘤/白血病蛋白-2对老年弥漫大B细胞淋巴瘤患者预后的影响[J].中华老年多器官疾病杂志,2018,17(7):481-485.
[14] 张慧芳,高 倩,王 彤.长链非编码RNA对弥漫大B细胞淋巴瘤患者的预后价值[J].中华疾病控制杂志,2019,23(8):998-1002.
[15] 王友群,唐小万.CHOP方案联合美罗华治疗弥漫大B细胞淋巴瘤78例回顾性分析[J].中华全科医学,2018,16(6):916-918.
[16] 庄娟娜,池伟东,方灿途.小柴胡汤加减治疗恶性淋巴瘤[J].中国中医药信息杂志,2019,26(6):121-123.
[17] 王志慧.复方君子汤辅助化疗治疗恶性淋巴瘤112例[J].江西中医药,2018,49(11):43-45.
[18] 杨美丰,任宏波.LncRNA HULC在弥漫性大B细胞淋巴瘤患者中表达及其临床意义[J].中华实用诊断与治疗杂志,2019,33(2):128-131.
[19] 杨耀林,田华琴,陈学彰,等.恒速输注华蟾素联合RCHOP方案治疗弥漫大B细胞淋巴瘤的疗效观察[J].内蒙古中医药,2019,38(3):53-54.
[20] 朱恒舟,桑天庆,季 漪,等.基于“消癌解毒方”中白花蛇舌草有效成分治疗肿瘤的靶点研究[J].中华中医药学刊,2020,38(5):132-135,276-277.

备注/Memo

备注/Memo:
基金项目:河北省中医药管理局科研计划项目(2017034)
更新日期/Last Update: 2021-04-09